These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 10980849)

  • 1. Combination drug therapy for combined hyperlipidemia.
    Guyton JR
    Curr Cardiol Rep; 1999 Sep; 1(3):244-50. PubMed ID: 10980849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statin-fibrate combination therapy.
    Shek A; Ferrill MJ
    Ann Pharmacother; 2001; 35(7-8):908-17. PubMed ID: 11485144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of hyperlipidemia with combined niacin-statin regimens.
    Guyton JR; Capuzzi DM
    Am J Cardiol; 1998 Dec; 82(12A):82U-84U; discussion 85-86U. PubMed ID: 9915667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century.
    Jacobson TA
    Curr Atheroscler Rep; 2001 Sep; 3(5):373-82. PubMed ID: 11487448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia.
    Yim BT; Chong PH
    Ann Pharmacother; 2003 Jan; 37(1):106-15. PubMed ID: 12503944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
    Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I
    Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LDL reduction: how low should we go and is it safe?
    Robinson JG
    Curr Cardiol Rep; 2008 Nov; 10(6):481-7. PubMed ID: 18950559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in the Use of Nonstatin Lipid-Lowering Therapy Among Patients With Coronary Heart Disease: A Retrospective Cohort Study in the Medicare Population 2007 to 2011.
    Bittner V; Deng L; Rosenson RS; Taylor B; Glasser SP; Kent ST; Farkouh ME; Muntner P
    J Am Coll Cardiol; 2015 Oct; 66(17):1864-72. PubMed ID: 26493657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism.
    Agouridis AP; Filippatos TD; Tsimihodimos V; Elisaf MS
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):355-66. PubMed ID: 21438815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients.
    Le NA; Jin R; Tomassini JE; Tershakovec AM; Neff DR; Wilson PW
    J Am Heart Assoc; 2013 Aug; 2(4):e000037. PubMed ID: 23926117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating dyslipidemic patients with lipid-modifying and combination therapies.
    Worz CR; Bottorff M
    Pharmacotherapy; 2003 May; 23(5):625-37. PubMed ID: 12741437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Niacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place?
    Zeman M; Vecka M; Perlík F; Hromádka R; Staňková B; Tvrzická E; Žák A
    Med Sci Monit; 2015 Jul; 21():2156-62. PubMed ID: 26210594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity of antilipidemic agents: facts and fictions.
    Xydakis AM; Jones PH
    Curr Atheroscler Rep; 2003 Sep; 5(5):403-10. PubMed ID: 12911851
    [No Abstract]   [Full Text] [Related]  

  • 14. [Fibrate and statine myopathy].
    Finsterer J
    Nervenarzt; 2003 Feb; 74(2):115-22. PubMed ID: 12596012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The combinations of statins and fibrates: pharmacokinetic and clinical implications].
    González Santos P
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():7-11. PubMed ID: 25043540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk for myopathy with statin therapy in high-risk patients.
    Ballantyne CM; Corsini A; Davidson MH; Holdaas H; Jacobson TA; Leitersdorf E; März W; Reckless JP; Stein EA
    Arch Intern Med; 2003 Mar; 163(5):553-64. PubMed ID: 12622602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nicotinic acid as a lipid-modifying drug--a review.
    Julius U; Fischer S
    Atheroscler Suppl; 2013 Jan; 14(1):7-13. PubMed ID: 23357134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suggested clinical approach for the diagnosis and management of 'statin intolerance' with an emphasis on muscle-related side-effects.
    Sivashanmugarajah A; Fulcher J; Sullivan D; Elam M; Jenkins A; Keech A
    Intern Med J; 2019 Sep; 49(9):1081-1091. PubMed ID: 31507054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of statin and fibrate combination therapy in lipid management.
    Kota SK; Meher LK; Rao ES; Jammula S; Modi KD
    Diabetes Metab Syndr; 2012; 6(3):173-4. PubMed ID: 23158983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.